Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.

Breast cancer research : BCR - 1 Jan 2008

Liedtke Cornelia, Cardone Luca, Tordai Attila, Yan Kai, Gomez Henry L, Figureoa Luis J Barajas, Hubbard Rebekah E, Valero Vicente, Souchon Eduardo A, Symmans W Fraser, Hortobagyi Gabriel N, Bardelli Alberto, Pusztai Lajos

Abstract excerpt

INTRODUCTION: In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer. METHODS: Tumor DNA from 140 patients with stage II-III breast cancer undergoing neoadjuvant chemotherapy was sequenced for PIK3CA mutations on exons 1, 9, and 20. Mutation status was correlated with clinical/pathological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Lymphatic Metastasis

Share to Neoadjuvant Therapy

Share to Receptor, ErbB-2

Share to Receptors, Progesterone

Share to Taxoids

Source

Open in PubMed Open full text

Identifiers

PMID: 18371219
DOI: 10.1186/bcr1984
PMCID: PMC2397526

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.PMID 18371219Read ↗

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials.Semantic proximity Read ↗

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Semantic proximity Read ↗

PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

Analysis of PIK3CA mutations in breast cancer subtypes.Semantic proximity Read ↗

High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.Semantic proximity Read ↗

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.Semantic proximity Read ↗

PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients.Semantic proximity Read ↗

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.Semantic proximity Read ↗

Clinicopathological and prognostic analysis of PIK3CA mutated invasive breast cancer in Chinese women.Semantic proximity Read ↗

PIK3CA mutations in breast cancerSemantic proximity Read ↗

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.